Home / Health / Ozempic Launches in India: Diabetes & Weight Game-Changer?
Ozempic Launches in India: Diabetes & Weight Game-Changer?
12 Dec
Summary
- Ozempic, a GLP-1 receptor agonist, is now available in India for type 2 diabetes.
- The drug helps manage blood sugar, aids weight loss, and offers cardiovascular benefits.
- Generic versions are expected in 2026, potentially lowering costs and increasing access.
India has welcomed Ozempic, the semaglutide-based medication, marking a significant milestone for the country's healthcare landscape. Approved in September 2025 for adults with type 2 diabetes, this GLP-1 receptor agonist is now available, offering a new therapeutic option. Its dual action addresses both glycemic control and weight management, crucial for India's extensive population dealing with diabetes and obesity.
The drug's benefits extend to potential cardiovascular and kidney health improvements, adding to its appeal. However, considerations such as potential side effects, eligibility criteria, and current costs are paramount. While doctors may leverage its weight-loss properties, the current Indian approval focuses on diabetes management.
As the patent for semaglutide is set to expire in India around March 2026, several major pharmaceutical companies are preparing to launch more affordable generic versions. This development is poised to enhance access to GLP-1 receptor agonists, potentially transforming diabetes care in India.
